A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas

Trial Profile

A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin
  • Indications Head and neck cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 07 Jun 2016 Results of retrospective analysis of this and other study (RTOG0129) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 03 Oct 2013 New source identified and integrated (M.D. Anderson Cancer Center: RTOG0522).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top